Department of Radiation Oncology, Taipei Hospital, Ministry of Health and Welfare, New Taipei City 242, Taiwan.
Department of Medicine, MacKay Medical College, New Taipei City 252, Taiwan.
Int J Mol Sci. 2023 Jan 21;24(3):2158. doi: 10.3390/ijms24032158.
A regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment for non-Hodgkin's lymphoma. Brown adipose tissue possesses anti-cancer potential. This study aimed to explore practical biomarkers for non-Hodgkin's lymphoma by analyzing the metabolic activity of adipose tissue.
Twenty patients who received R-CHOP for non-Hodgkin's lymphoma were reviewed. Positron emission tomography/computed tomography (PET/CT) images, lactate dehydrogenase (LDH) levels, and body mass index (BMI) before and after treatment were collected. Regions with a high standardized uptake value (SUV) in epicardial and orbital adipose tissue were selected and analyzed by a PET/CT viewer. The initial measurements and changes in the high SUV of epicardial and orbital adipose tissues, LDH levels, and BMI of treatment responders and non-responders, and complete and partial responders, were compared.
The volumes of high-SUV epicardial and orbital adipose tissues significantly increased in responders after R-CHOP ( = 0.03 and 0.002, respectively). There were significant differences between changes in the high-SUV volumes of epicardial and orbital adipose tissues ( = 0.03 and 0.001, respectively) and LDH levels ( = 0.03) between responders and non-responders. The changes in high-SUV epicardial adipose tissue volumes were greater among complete responders than partial responders ( = 0.04). Poorer treatment responses were observed in patients with lower high-SUV epicardial adipose tissue volumes and higher LDH levels after R-CHOP ( = 0.03 and 0.03, respectively).
The preliminary results of greater changes in high-SUV epicardial and orbital adipose tissue volumes among responders indicate that brown adipose tissue could be considered a favorable prognostic biomarker.
利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）方案是治疗非霍奇金淋巴瘤的标准治疗方法。棕色脂肪组织具有抗癌潜力。本研究旨在通过分析脂肪组织的代谢活性来探索非霍奇金淋巴瘤的实用生物标志物。
回顾了 20 例接受 R-CHOP 治疗的非霍奇金淋巴瘤患者。收集了治疗前后的正电子发射断层扫描/计算机断层扫描（PET/CT）图像、乳酸脱氢酶（LDH）水平和体重指数（BMI）。通过 PET/CT 查看器选择和分析心外膜和眶内脂肪组织中高标准化摄取值（SUV）的区域。比较了治疗反应者和非反应者以及完全和部分反应者的初始测量值和心外膜和眶内高 SUV 脂肪组织、LDH 水平和 BMI 的变化。
R-CHOP 后反应者的心外膜和眶内高 SUV 脂肪组织体积明显增加（分别为 = 0.03 和 0.002）。反应者和非反应者之间，心外膜和眶内高 SUV 脂肪组织体积变化（分别为 = 0.03 和 0.001）和 LDH 水平（ = 0.03）存在显著差异。完全反应者的高 SUV 心外膜脂肪组织体积变化大于部分反应者（ = 0.04）。R-CHOP 后高 SUV 心外膜脂肪组织体积较小和 LDH 水平较高的患者治疗反应较差（分别为 = 0.03 和 0.03）。
反应者高 SUV 心外膜和眶内脂肪组织体积变化较大的初步结果表明，棕色脂肪组织可作为一种有利的预后生物标志物。
